Effective antihypertensive therapy is crucial for preventing cardiovascular events; however, blood pressure (BP) control rates remain poor. The objective of this analysis was to determine the efficacy of olmesartan/ amlodipine in age, severity and gender-based subgroups of patients with moderate-to-severe hypertension uncontrolled by amlodipine monotherapy. Patients with uncontrolled BP after 8 weeks' amlodipine 5 mg monotherapy (n ¼ 755) were randomized to continue amlodipine 5 mg or receive olmesartan (10-40 mg) plus amlodipine 5 mg for 8 weeks. Patients whose BP remained suboptimal were uptitrated to olmesartan/ amlodipine 20/5, 40/5 or 40/10 mg. Changes in BP and numbers of controlled patients were calculated separately to assess efficacy in patients aged o65 or X65 years, in those with moderate or severe hypertension, and in males and females. The antihypertensive effects of olmesartan/amlodipine were similar in patients aged o65 and X65 years of age. Compared with patients with moderate hypertension at baseline, those with severe hypertension tended to show higher decreases in BP, but achieved lower goal rates despite this. Females showed larger mean reductions in diastolic (1.61 mm Hg; P ¼ 0.003) and systolic BP (1.72 mm Hg; P ¼ 0.053) than males, independent of age and dose. This gender difference appeared to be higher and more consistent across dose groups for patients o50 years of age, but the difference in the pattern between both age groups was not statistically significant (P ¼ 0.1526). These results suggest that olmesartan/amlodipine is effective and safe in a wide range of patients, regardless of age or hypertension severity. Small differences in responsiveness between females and males may exist, which require further investigation.
Introduction
Hypertension is a widespread and common phenomenon that represents a major public health issue due to its nature as a major independent risk factor for cardiovascular events. [1] [2] [3] A large amount of clinical data has demonstrated that blood pressure (BP) reduction is central to reducing the risk of cardiovascular events. [4] [5] [6] Consequently, European and American guidelines for the management of hypertension recommend that all individuals should achieve a BP target of o140/90 mm Hg, with a more stringent target of o130/80 mm Hg for patients with diabetes. 7, 8 However, despite some improvements in recent years, the proportion of hypertensive patients achieving BP targets remains worryingly low. 3 For example, in Western European countries, estimates of patients with controlled BP range from 27 to 46%. 3, 9 This shows that patients with a BP X140/90 mm Hg represent a serious challenge for physicians, and that large numbers of hypertensive patients remain at a substantial risk of cardiovascular outcomes. 10 Clinical experience has shown that most hypertensive patients will require combination therapy with two or more antihypertensive drugs to achieve BP goals. [11] [12] [13] Hypertension treatment guidelines now place increasing emphasis on the benefits of initiating treatment with combination therapy, particularly in patients whose diastolic BP (DBP) or systolic BP (SBP) exceeds the goal by 410 mm Hg or 420 mm Hg, respectively. 7, 8 Combining drugs from different classes is an effective way to increase antihypertensive power, and is recommended for drugs with complementary mechanisms of action, that is, where the combination produces a BP-lowering effect greater than that of either monotherapy component, and a favourable tolerability profile that reduces the frequency of undesirable effects. 8 The Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH) study has recently shown that in high-risk patients, blockade of the renin-angiotensin system with an angiotensin-converting enzyme inhibitor combined with the calcium channel blocker amlodipine was associated with a 20% reduction in cardiovascular morbidity and mortality, compared with angiotensin-converting enzyme inhibitor plus diuretic combination therapy. 14 Effective blockade of the renin-angiotensin system can also be achieved using angiotensin receptor blockers, which are associated with fewer adverse events than angiotensin-converting enzyme inhibitors, and fixed dose combinations of angiotensin receptor blockers with amlodipine are now becoming available. A combination of the angiotensin receptor blocker olmesartan medoxomil with amlodipine has recently been shown to be effective and well tolerated in a range of patients, including those with moderate-to-severe hypertension. [15] [16] [17] One of the studies that established the efficacy of the olmesartan/amlodipine combination used a nonresponder design. Patients who failed to achieve an adequate level of BP control after 8 weeks' treatment with amlodipine (5 mg per day) were randomized to 8 weeks of treatment with one of three dose combinations of olmesartan (10, 20 or 40 mg per day) plus amlodipine (5 mg per day), or to continue with amlodipine (5 mg) monotherapy. The study also included a further 8-week period of double-blind treatment, in which patients with suboptimal BP control had their treatment uptitrated. Thus, a key element in the design of this study was the need to determine the efficacy of the combination and of uptitration in patients who had not achieved BP control during the initial stages of treatment. As noted above, patients whose BP remains above 140/90 mm Hg are a common problem for physicians, and the results demonstrate that olmesartan combined with amlodipine provides an effective remedy for this challenge and delivers significant reductions in SBP and DBP and high levels of BP goal achievement. The study also provides an opportunity to ascertain whether the combination is effective in specific patient groups. For example, certain BP-lowering treatment regimens have been reported to differ between men and women, [18] [19] [20] whereas others have shown no evidence of a gender difference. 21 Also, BP is known to increase with advancing age and it is important to determine that antihypertensive therapies are effective in older patients.
This report describes analyses of BP changes and goal rate achievement in several subgroups of the study reported by Volpe et al. 17 and examines the effects of treatment in age-, gender-and hypertension severity-defined subgroups during the 8-week period of randomized, double-blind treatment and the subsequent 8-week uptitration period.
Methods

Study population and design
This was a 52-week, multicentre, multinational study in which the primary efficacy parameter and various secondary parameters were based upon randomized, double-blind, parallel-group treatment during the first 24 weeks. 17 Briefly, male and female patients aged X18 years with moderate-to-severe essential hypertension were enrolled. The criteria for inclusion in the study were as follows: newly diagnosed patients and those receiving treatments other than amlodipine 5 mg or 10 mg, with seated DBP (SeDBP) X100 mm Hg, seated SBP (SeSBP) X160 mm Hg and 24-h DBP measured by ambulatory BP monitoring X84 mm Hg with X30% of daytime DBP 490 mm Hg; patients receiving amlodipine 5 or 10 mg at screening, with a diagnosis of moderateto-severe hypertension before amlodipine therapy and SeDBP X90 mm Hg, SeSBP X140 mm Hg, and 24-h DBP X80 mm Hg with X30% of daytime DBP 485 mm Hg while receiving amlodipine. The criteria for uptitration in Period III were SeSBP X140 mm Hg and SeDBP X90 mm Hg. Thus, patients who did not fulfil each of the BP criteria, for example, with a BP of 145/85 mm Hg, did not undergo dose titration, and did not reach BP goal. For this reason, some patients who had not reached goal at the end of Period II were not uptitrated.
After Period III, all patients entered a 28-week open-label treatment period, which has been described and is not of relevance to the present analyses. 22 
Efficacy variables
Analyses were performed on efficacy parameters (mean changes in seated BP and the proportion of patients who reached BP goal) for Periods II and III for age subgroups (o65 years and X65 years), gender subgroups (male and female) and hypertension severity subgroups (moderate and severe). Hypertension severity was classified as follows:
Moderate: SBP 4159 mm Hg and p179 mm Hg; DBP 499 mm Hg and p109 mm Hg Severe: SBP 4179 mm Hg; DBP 4109 mm Hg Patients who were already taking amlodipine (5 or 10 mg) at the start of the study were evaluated separately.
Hypertension severity was only determined for newly diagnosed patients and those receiving nonamlodipine antihypertensive medications. When a patient's SeSBP and SeDBP fell into different categories of severity, the higher category was used.
Safety variables
Safety assessments included the incidence of treatment-emergent adverse events, physical examinations, and measurement of vital signs, laboratory parameters and electrocardiograms.
Statistical analysis
For the subgroup analyses, descriptive statistics were computed for baseline values and changes from baseline to the end of the period. Statistical analyses were performed using last observation carried forward on the full analysis sets for Period II and Period III, which included all randomized patients who received at least one dose of double-blind study medication during the relevant period and had a baseline DBP measurement and at least one post-randomization DBP measurement. Linear least squares models were used to analyse the change in BP through Period II as a function of gender, age group (split at 50 years and at 65 years), hypertension severity group and treatment group; both focused models including only one subgroup term and more comprehensive models including several subgroup terms, and their interactions were fitted to Period II data. The threshold of 50 years for age groups was chosen to differentiate between pre-and post-menopausal women. Baseline BP was always included in statistical models as a continuous covariate. Logistic regression was used for the analysis of the qualitative variable BP goal achievement. BP changes after uptitration were tested using paired t-tests. All P-values are based on two-sided tests.
Results
Patients
Of 1997 patients screened, 1017 entered open-label monotherapy (Period I) and 755 were randomized to 8 weeks of double-blind treatment (Period II). Of these, 706 entered the 8-week double-blind uptitration period (Period III). The full analysis sets used for the subgroup analyses in Periods II and III consisted of 746 and 705 patients, respectively.
Among the 746 patients of the full analysis set who were analysed for Period II, the mean age was 55.7 years (78.8% were aged o65 years and 21.2% were aged X65 years), 61.1% were male, 99.7% (all except two) were Caucasian, and mean baseline BP at week 0 was 164.4/101.9 mm Hg.
At the start of Period II, the four treatment groups had comparable demographic and other characteristics, with no statistically significant between-group differences ( Table 1) . 
Abbreviations: AML, amlodipine; DBP, diastolic blood pressure; OLM, olmesartan; SBP, systolic blood pressure.
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Period II Each of the separate analyses (age, hypertension severity and gender) showed that larger reductions in SeSBP and SeDBP (Figures 1-3) were observed with olmesartan/amlodipine combination treatment than with amlodipine 5 mg monotherapy (Po0.001 for SeSBP and for SeDBP, for the comparison of the two highest combination groups with amlodipine 5 mg). Moreover, each analysis showed that reductions in SeSBP and SeDBP were generally dosedependent, with the greatest reductions seen in patients who received olmesartan/amlodipine 40/5 mg, the highest dose combination used in Period II.
Effect of age
Changes in SeDBP were similar in the two age groups (the overall mean reduction in SeDBP was 0.60 mm Hg higher in patients aged X65 years; P ¼ 0.35). Changes in SeSBP were also generally similar ( Figure 1 ) in patients aged o65 compared with those aged X65 years (the overall mean reduction in SeSBP was 0.57 mm Hg lower in patients aged X65 years, P ¼ 0.59). There was no consistent difference in goal rate achievement (o130/ 80 mm Hg for patients with diabetes) between older and younger patients across the different dosage combinations of olmesartan/amlodipine ( Table 2) .
Effect of hypertension severity Some small variations in the mean changes in SeDBP and SeSBP were seen between patients with moderate and severe hypertension and those who had been taking amlodipine 5 mg before the study. However, none of these severity subgroups showed Efficacy of olmesartan/amlodipine in patient subgroups RE Schmieder and M Böhm consistently greater SeDBP or SeSBP reductions across the different dose groups (P40.2 for the between-group difference in SeDBP and SeSBP, based on statistical models with adjustment for dose group and baseline BP at Period II) (Figure 2) . The proportion of patients who reached BP goal during Period II tended to be lower in patients with severe hypertension compared with patients with moderate hypertension and in those who received amlodipine 5 mg before the study (Table 3) , although these differences were not statistically significant (P ¼ 0.071). Patients with severe hypertension showed a clear and consistent increase in achieved BP goal rates with increasing dose combination ( Table 3 ).
Effect of gender
Female patients showed larger mean reductions in SeDBP and SeSBP than males (Figure 3) . In addition, a higher proportion of female patients reached BP goal in each group except for the olmesartan/amlodipine 40/5 mg group (Po0.05) ( Table 4) . Statistical analysis using a model adjusted for treatment group and baseline BP showed that in females, the mean reductions in SeDBP and SeSBP were 1.61 and 1.72 mm Hg greater (P ¼ 0.003 and P ¼ 0.0533, respectively) than those seen in males. Figure 3 also indicates a decreasing trend for the difference in SeSBP (P ¼ 0.13), but less so than for SeDBP (P ¼ 0.45), between male and female patients as the dose of olmesartan increases.
To assess whether a difference might exist between pre-and post-menopausal women in their response to treatment, further analysis of gender differences, which included an age group split at the threshold of 50 years, and interaction terms between age group, gender and treatment was carried out. For the change in SeDBP, again, a statistically significant main effect (À2.13 mm Hg; Po0.01) of gender was observed. This gender difference was higher (and more consistent across dose groups) for patients o50 years of age, but the difference in the pattern between age 450 and o50 years was not statistically different (P ¼ 0.1526). For the change in SeSBP, a borderline significant main effect of gender was seen (1.97 mm Hg; P ¼ 0.066) and there was no significant interaction of gender with other terms. Data are included only for patients whose dose regimen was uptitrated in Period III; uptitration from and to is indicated as column name.
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Period III In patients whose BP had been inadequately controlled during Period II, uptitration to higher doses led to additional statistically significant mean reductions in SeSBP (10.8 mm Hg; Po0.0001) and SeDBP (7.1 mm Hg; Po0.0001) and higher percentages of patients achieving BP goals during period III in each subgroup (Tables 2-4 ). These additional effects of uptitration on SeSBP and SeDBP were generally dose dependent, with the largest decreases seen with olmesartan/amlodipine 40/10 mg (data not given). It should be noted that the overall BP dose response at the end of Period III was affected by the selection process of uptitration: more patients who received lower dose combinations during Period II were uptitrated compared with those treated with higher dose combinations. In the amlodipine 5 mg group, 58.2% of patients were uptitrated, whereas in the olmesartan 10, 20 and 40 mg with amlodipine 5 mg groups, the proportions were 43.4, 31.0 and 30.6%, respectively. Thus, in a sense, the decreasing percentage of patients who required uptitration represents the dose response.
Effect of age
Across all treatment groups, the mean overall change in both SeDBP and SeSBP was greater in uptitrated patients aged X65 years (À8.1/ À12.8 mm Hg) compared with those aged o65 years (À6.9/À10.3 mm Hg). However, the difference between uptitrated patients X65 years compared with uptitrated patients aged o65 years was not significant for SeDBP (1.18 mm Hg; P ¼ 0.24) or SeSBP (2.27 mm Hg; P ¼ 0.16). A larger proportion of patients aged X65 years achieved BP goal (overall 46.8%) compared with patients aged o65 years (34.3%; P ¼ 0.07), although the relatively low numbers of older patients in some of the treatment groups make this interpretation less certain.
Effect of hypertension severity
Across all treatment groups, the mean overall change in both SeDBP and SeSBP during Period III was greatest in patients who had received amlodipine 5 mg before the study (À8.4/À12.8 mm Hg, both P ¼ 0.031 after adjustment for dose in Period II). The mean changes in SeDBP and SeSBP in uptitrated patients with moderate hypertension (À6.3/À9.1 mm Hg) were generally comparable with those seen in patients with severe hypertension (À5.9/À9.5 mm Hg). Patients with moderate and severe hypertension also showed similar increases in levels of goal rate achievement after uptitration in Period III (P ¼ 0.16 for comparison between severity classes). 
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Looking at the change in BP of all patients from week 0 to the end of Period III, patients with severe hypertension at week 0 showed larger mean reductions in SeSBP and SeDBP compared with those with moderate hypertension (Table 5 ).
Effect of gender
In uptitrated patients, greater mean reductions in both DBP and SBP were observed in females (À7.9/À12.4 mm Hg) compared with males (À6.7/ À10.0 mm Hg) (P ¼ 0.21 for DBP and P ¼ 0.091 for SBP). Furthermore, after uptitration females showed higher rates of BP goal achievement (overall 13.6% higher; P ¼ 0.03) than males.
Safety assessments
No important differences in the incidence of treatment-emergent adverse events or the types of treatment-emergent adverse events were noted between age subgroups, gender subgroups or hypertension severity subgroups.
Discussion
The results of these subgroup analyses reflect the findings reported by Volpe et al. 17 for the main treatment groups in the primary analysis of this study. For each subgroup, the combination of olmesartan/amlodipine was more effective than amlodipine 5 mg monotherapy in reducing and controlling BP in patients who had failed to achieve BP control with open-label amlodipine 5 mg. Furthermore, the size of BP reductions in each subgroup were generally dose dependent, further reductions in SeSBP and SeDBP were achieved by uptitration in patients with a suboptimal response, and the largest BP reductions were generally seen with the combination of olmesartan 40 mg plus amlodipine. These results also indicate that olmesartan/amlodipine combination therapy is effective in various subgroups of hypertensive patients, although females appeared to show somewhat larger BP reductions than males.
The extent of BP reductions with olmesartan/ amlodipine combination therapy were similar in older (X65 years) and younger (o65 years) patients. This is important as BP, particularly SBP, tends to increase with age and hypertension occurs more frequently in older patients. 23, 24 The benefits of BP reduction in older patients are similar to those observed in younger patients in terms of reducing cardiovascular risk. A recent meta-analysis of randomized trials showed that lowering BP produces similar reductions in the risks of cardiovascular events in patients aged o65 years and in those aged X65 years. 25 In addition, the HYVET (Hypertension in the Very Elderly Trial) study has also shown that treating hypertension reduces the risk of death from stroke, and from any cause in very elderly patients (aged 480 years). 26 Of further relevance here is a recent analysis that looked at patients in this study who received olmesartan/ amlodipine 40/5 mg or 40/10 mg during the final open-label phase. This found that baseline SeSBP was related to the change in SeSBP achieved at the end of the study, so that patients with higher baseline levels of SeSBP showed larger reductions. Indeed, by the end of the study, more than half of all patients showed a reduction in SeSBP of X30 mm Hg, and 82.2% had achieved SeSBP of o140 mm Hg. 27 Taken with the present findings, this indicates that olmesartan/amlodipine combination therapy may offer benefits in terms of cardiovascular risk reduction in older patients, including those with substantially elevated SBP.
The olmesartan/amlodipine combination produced similar BP reductions in patients with moderate hypertension compared with patients with severe hypertension. The rates of BP goal achievement in patients with severe hypertension were lower than in those with moderate hypertension, which undoubtedly relates to the higher baseline BP levels in the severe group, an effect also noted in previous studies and analyses. For example, a review of randomized trials showed that in studies involving patients with a high level of SeSBP at baseline (4160 mm Hg), the mean level of SeSBP at study end remained 4140 mm Hg. 28 A Framingham cohort analysis found that hypertension severity at baseline was a strong predictor for lack of BP control, and a recent US electronic database analysis confirmed that 12 months after initiation of antihypertensive therapy, a smaller proportion of patients with Stage 2 hypertension achieved BP control compared with patients with Stage 1 hypertension. 29, 30 Overall, for all patients, the mean change in both SeDBP and SeSBP from baseline (week 0) to the end of Period III was greater in patients with severe hypertension compared with those with moderate hypertension (Table 5) . Observations similar to these highlight the difficulties that patients with elevated BP pose for physicians and the need to evaluate efficacy in harder-totreat patients. The results of the present analyses indicate that olmesartan/amlodipine provides an effective option for such challenging patients.
Olmesartan/amlodipine treatment produced significant dose-related reductions in BP in each gender, and females showed larger BP reductions than males. Statistical analysis showed furthermore that the main effect of gender on SeDBP was independent of dose, and not related to the drug combination used. This gender effect was further analysed by looking at BP changes using an arbitrary age threshold of 50 years to explore the possibility that the menopause might be involved. We have already described this above, there was no statistically significant interaction between gender, age group o50 or X50 years, or dose group. The issue of whether males and females respond differently to antihypertensive therapy is not new and remains an area of uncertainty. Some studies have suggested that discrepancies in cardiovascular risk between males and females may involve genderrelated differences in response to antihypertensive therapy. [18] [19] [20] For example, a large registry study involving 29 148 essential hypertensive patients receiving antihypertensive treatment found that a greater proportion of women achieved BP control, measured by ambulatory BP monitoring, compared with men. 31 However, a meta-analysis of data from 31 trials involving more than 100 000 male and nearly 90 000 female patients with hypertension found no evidence of a difference in the effects of BP-lowering treatment regimens between men and women. 21 In this study, there were no differences across subgroup categories in the incidence or type of adverse effects. Full tolerability data from this trial were previously reported 17 and were consistent with the safety profiles of angiotensin receptor blocker/calcium channel blocker combinations described in the literature. The results from these subgroup analyses show that the combination of olmesartan/amlodipine is well tolerated in a wide range of patients.
This study has some limitations. First, it was not designed to detect differences between subgroups. Second, the size of some subgroups reduces the ability to detect a subgroup effect of treatment dose on BP response. These results should therefore be regarded as exploratory, with a need for verification by other studies or meta-analyses. Furthermore, the lack of clinical end points means that no insight is provided into the cardiovascular benefits of treatment. However, the analyses conducted by the Prospective Studies Collaboration indicate that for each 10 mm Hg reduction in SBP there is an approximate reduction of 40 and 30% in the risk of mortality due to stroke and ischaemic heart disease or other vascular causes, respectively. 6 In the primary analysis of this study, the additional benefit of combination therapy in terms of SBP reduction during Period II was approximately 7 mm Hg for patients who received olmesartan/ amlodipine 40/5 mg. 17 The present analyses show SBP changes of approximately similar magnitude in the subgroups, with further additional BP reductions seen during Period III in inadequately controlled patients. In addition to BP reduction per se, the results of the recent ACCOMPLISH trial indicate that treatment with a renin-angiotensin system blocker-calcium channel blocker combination may be of particular benefit in reducing cardiovascular risk in certain groups of patients, such as those with diabetes, metabolic syndrome or impaired glucose tolerance.
14 Thus, it would be reasonable to expect a worthwhile benefit in terms of cardiovascular risk reduction from the BP reductions seen in this study, plus potential additional effects that may be obtained in certain patients.
In conclusion, the high number of patients with BP 4140/90 mm Hg remains a cause for concern in many countries, and the treatment of such patients represents a major challenge for physicians. The recent study by Volpe et al. 22 demonstrated that the combination of olmesartan/amlodipine may help to address this challenge by effectively reducing and controlling BP in patients who had not achieved adequate BP control with amlodipine monotherapy. The present analyses provide further insights into the efficacy of this combination, confirming that the combination of olmesartan/amlodipine is effective and safe in a range of patients, regardless of age, hypertension severity or gender. Further studies are required to determine any clinical relevance of a possibly greater sensitivity of females to the combination.
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What is known about topic K Effective antihypertensive therapy is crucial for reducing cardiovascular risk. Despite this, blood pressure (BP) control rates remain suboptimal, and the high number of patients with BP 4140/90 mmHg remains a cause for concern in many countries, representing a major challenge for physicians. K Clinical experience has shown that most hypertensive patients require combination therapy with two or more antihypertensive agents to achieve BP goal. K Combination therapy with the angiotensin receptor blocker olmesartan and the calcium channel blocker amlodipine has been shown to effectively reduce and control BP in a range of hypertensive patients.
What this study adds K This present analysis provides further insights into the efficacy of antihypertensive therapy with olmesartan/ amlodipine in age, hypertension severity and gender-based subgroups of patients with moderate-to-severe hypertension not adequately controlled by amlodipine monotherapy. K Findings from this subgroup analysis show that combination therapy with olmesartan/amlodipine is effective and well tolerated in a range of patients, regardless of age, hypertension severity or gender, although there are some hints that female patients respond slightly better.
